Navika D. Shukla

Navika D. Shukla

Auto-generated profile, based on publicly available information

Navika D. Shukla

Department of Medicine, University of Chicago, Chicago, IL

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2020 in JNCI Cancer Spectrum
Verified
Journal Article
Open access
PDF file
AAAser Abrha
Aser Abrha
NSNavika D Shukla
Navika D Shukla
RHRachel Hodan
Rachel Hodan
TLTeri Longacre
Teri Longacre
SRShyam Raghavan
Shyam Raghavan
SHSigurdis Haraldsdottir
Sigurdis Haraldsdottir
In light of recent Food and Drug Administration (FDA) approval of immune checkpoint inhibitors for mismatch repair deficient (dMMR) malignancies, identifying patients with dMMR malignancies has become increasingly important. Although screening for dMMR in colorectal cancer (CRC) is recommended, it is less common for extracolonic gastrointestinal (GI) malignancies. At Stanford Comprehensive Cancer Institute (SCCI), all GI malignancies have been screened for dMMR via immunohistochemistry since January 2016. In this study, we conducted a retrospective review of all patients with GI malignancies screened for dMMR between January 2016 and December 2017. Tumor sequencing was performed on cases negative for germline pathogenic variants where tumor material was available. A total of 1425 consecutive GI malignancies were screened for dMMR at SCCI during the study period, and 1374 were included for analysis. dMMR was detected in 7.2% of all GI malignancies. We detected the highest prevalence of dMMR in gastric (15 of 150, 10.0%) followed by colorectal (63 of 694, 9.1%), pancreatic (13 of 244, 5.3%), and gastroesophageal malignancy (6 of 132, 4.5%) patients. Lynch syndrome was the most common etiology for dMMR in colorectal cancer (41.5%), double somatic (confirmed or possible) pathogenic variants the most common etiology in pancreatic cancer (44.4%), and somatic MLH1 hypermethylation the most common etiology in gastric (73.3%) and gastroesophageal cancer (83.3%). Given the relatively high incidence of dMMR in GI malignancies, we recommend screening all GI malignancies. Our results suggest that although a rare occurrence, double somatic pathogenic variants may be a biologically significant pathway causing dMMR in pancreatic cancer.

13 July 2021 in Head & Neck
Verified
Journal Article
Closed access
PDF file
NSNavika Shukla
Navika Shukla
YMYifei Ma
Yifei Ma
UMUchechukwu C. Megwalu
Uchechukwu C. Megwalu

6 October 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
ASAmeen Salahudeen
Ameen Salahudeen
KYKanako Yuki
Kanako Yuki
JSJose A. Seoane
Jose A. Seoane
AMAmanda T. Mah
Amanda T. Mah
ASAmber R. Smith
Amber R. Smith
CKCalvin J Kuo
Calvin J Kuo
SUMMARY: Somatic copy number gains are pervasive in many cancer types, yet their roles in oncogenesis are often poorly explored. This lack of understanding is in part due to broad extensions of copy gains across cancer genomes spanning large chromosomal regions, obscuring causal driver loci. Here we employed a multi-tissue pan-organoid modeling approach to validate candidate oncogenic loci identified within pan-cancer TCGA data by the overlap of extreme copy number amplifications with extreme expression dysregulation for each gene. The candidate outlier loci nominated by this integrative computational analysis were functionally validated by infecting cancer type-specific barcoded full length cDNA lentiviral libraries into cognate minimally transformed human and mouse organoids bearing initial oncogenic mutations from esophagus, oral cavity, colon, stomach, pancreas and lung. Presumptive amplification oncogenes were identified by barcode enrichment as a proxy for increased proliferation. Iterative analysis validated DYRK2 at 12q15, encoding a serine-threonine kinase, as an amplified head and neck squamous carcinoma oncogene in p53 -/- oral mucosal organoids. Similarly, FGF3 , amplified at 11q13 in 41% of esophageal squamous carcinomas, was validated in p53 -/- esophageal organoids in vitro and in vivo with pharmacologic inhibition by small molecule and soluble receptor FGFR antagonists. Our studies establish the feasibility of pan-organoid contextual modeling of pan-cancer candidate genomic drivers, enabling oncogene discovery and preclinical therapeutic modeling.

15 November 2022 in Blood
Verified
Journal Article
Open access
DGDaria Gaut
Daria Gaut
COCaspian Oliai
Caspian Oliai
JBJonathan Boiarsky
Jonathan Boiarsky
SZShiliang Zhang
Shiliang Zhang
TATali Azenkot
Tali Azenkot
GSGary J. Schiller
Gary J. Schiller